Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Drug Metabolism And Disposition

• Publication date

  2007-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.107.017145PMID 17664247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10.

  2007cited by this paper
• Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

  2006cited by this paper
• IMPORTANCE OF UDP-GLUCURONOSYLTRANSFERASE 1A10 (UGT1A10) IN THE DETOXIFICATION OF POLYCYCLIC AROMATIC HYDROCARBONS: DECREASED GLUCURONIDATIVE ACTIVITY OF THE UGT1A10139LYS ISOFORM

  2006cited by this paper
• Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4.

  2006cited by this paper
• Extended adjuvant endocrine therapy of early breast cancer

  2005cited by this paper
• Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

  2005cited by this paper
• Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

  2005cited by this paper
• Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.

  2004cited by this paper
• Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium.

  2004cited by this paper
• Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4.

  2004cited by this paper
• Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes

  2004influential reference
• Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4.

  2004influential reference
• Overview of the main outcomes in breast-cancer prevention trials.

  2003cited by this paper
• New approaches to the endocrine prevention and treatment of breast cancer

  2003cited by this paper
• Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases.

  2002cited by this paper
• Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes.

  2002cited by this paper
• [Tamoxifen and breast cancer].

  2002cited by this paper
• Identification of Tamoxifen−DNA Adducts Induced by α-Acetoxy-N-desmethyltamoxifen

  2000cited by this paper
• Risk and prognosis of endometrial cancer after tamoxifen for breast cancer

  2000cited by this paper
• O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9.

  2000cited by this paper
• Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.

  2000cited by this paper
• Identification of tamoxifen-DNA adducts induced by alpha-acetoxy-N-desmethyltamoxifen.

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by rat UDP-glucuronosyltransferase 2B1.

  1999cited by this paper
• Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins.

  1998cited by this paper
• Tamoxifen and risk of idiopathic venous thromboembolism.

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Risk of endometrial cancer after tamoxifen treatment of breast cancer.

  1994cited by this paper
• Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.

  1993cited by this paper
• Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.

  1993cited by this paper
• Role of N-glucuronidation in benzidine-induced bladder cancer in dog.

  1992influential reference
• [Tamoxifen and breast cancer].

  1991cited by this paper
• Synthesis and antiestrogenic activity of the compounds related to the metabolites of (E)-4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]- 2-(4-isopropylphenyl)-1-butenyl]phenyl monophosphate (TAT-59) [corrected].

  1991cited by this paper
• Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.

  1991cited by this paper
• Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.

  1990cited by this paper
• Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.

  1989influential reference
• Tamoxifen in the treatment of breast cancer.

  1988influential reference
• A general assay for UDPglucuronosyltransferase activity using polar amino-cyano stationary phase HPLC and UDP[U-14C]glucuronic acid.

  1986cited by this paper
• Synthesis and receptor-binding affinity of fluorotamoxifen, a possible estrogen-receptor imaging agent.

  1985cited by this paper
• Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen.

  1982cited by this paper
• A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.

  1977cited by this paper

• Identification of human hepatic UDP-glucuronosyltransferases involved in the glucuronidation of temazepam.

  2025cites this paper
• Deciphering Drug Resistance: Investigating the Emerging Role of Hyaluronan Metabolism and Signaling and Tumor Extracellular Matrix in Cancer Chemotherapy

  2024cites this paper
• Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid–Oxazepam Drug Interactions

  2024cites this paper
• Impact of CYP2D6, CYP2C9/19, CYP3A4, UGT, and SULT Variability on Tamoxifen Metabolism in Breast Cancer Treatment

  2023cites this paper
• In vitro hepatic metabolism of the natural product quebecol

  2023influential citation
• Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors

  2022cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells

  2021cites this paper
• Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin

  2021cites this paper
• A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer

  2021cites this paper
• Homology Modeling of Human Uridine-5′-diphosphate-glucuronosyltransferase 1A6 Reveals Insights into Factors Influencing Substrate and Cosubstrate Binding

  2020cites this paper
• Effect of 2.5 hr-interval single oral combination treatment of Gamisoyo-san with Tamoxifen on the pharmacokinetics profiles of Tamoxifen in rats

  2020cites this paper
• Genome-wide gene expression analysis reveals novel insights into the response to nitrite stress in gills of Branchiostoma belcheri.

  2019cites this paper
• Effects of mixed formulation of tamoxifen and blue honeysuckle on the pharmacokinetics profiles of tamoxifen after single oral administration

  2019cites this paper
• Pharmacokinetics and Safety of Bazedoxifene in Hepatically Impaired and Healthy Postmenopausal Women

  2018cites this paper
• RS7435335 located in the UGT2B7 gene may be a possible genetic marker for the clinical response and prognosis of breast cancer patients receiving neoadjuvant chemotherapy

  2018cites this paper
• Effect of (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats

  2017cites this paper
• Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats

  2017cites this paper
• Integrating Personalization of Treatment with Tamoxifen into Pharmacy Practice Via Clinical Pharmacist Role in Therapy Management

  2016cites this paper
• Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients

  2016cites this paper
• Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines

  2016cites this paper
• The role of glucuronidation in drug resistance.

  2016cites this paper
• Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (1)

  2016cites this paper
• [Glucuronidation of antitumour therapeutics--detoxification, mechanism of resistance or prodrug formation?].

  2015cites this paper
• Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer

  2015cites this paper
• Induction of UDP-Glucuronosyltransferase 2B15 Gene Expression by the Major Active Metabolites of Tamoxifen, 4-Hydroxytamoxifen and Endoxifen, in Breast Cancer Cells

  2015influential citation
• Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients

  2015cites this paper
• MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors

  2015cites this paper
• Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.

  2015cites this paper
• A Potential Role for Human UDP-Glucuronosyltransferase 1A4 Promoter Single Nucleotide Polymorphisms in the Pharmacogenomics of Tamoxifen and Its Derivatives

  2014influential citation
• Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis.

  2014cites this paper
• UGT2B Gene Expression Analysis in Multiple Tobacco Carcinogen-Targeted Tissues

  2014cites this paper
• Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences.

  2014cites this paper
• A potential role for human UDP‐glucuronosyltransferase 1A4 promoter SNPs in the pharmacogenomics of Tamoxifen and its derivatives (1141.13)

  2014cites this paper
• UGT 2 B Gene Expression Analysis in Multiple Tobacco Carcinogen-Targeted Tissues s

  2014cites this paper
• Development of a multi-gene PCR assay for the prediction of the response to hormone therapy in breast cancer

  2014cites this paper
• Pharmacogenomics–Pharmacoepigenomics of Breast Cancer Therapy: Clinical Implications

  2014cites this paper
• DMD058016 1392..1400

  2014influential citation
• Regulation of UDP-Glucuronosyltransferase 1A1 Expression and Activity by MicroRNA 491-3p

  2014cites this paper
• Importance of UDP-Glucuronosyltransferases 2A2 and 2A3 in Tobacco Carcinogen Metabolism

  2013cites this paper
• Tamoxifen pharmacokinetics and pharmacogenetics in endocrine sensitive breast cancer patients

  2013cites this paper
• Characterization of Raloxifene Glucuronidation: Potential Role of UGT1A8 Genotype on Raloxifene Metabolism In Vivo

  2013cites this paper
• Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights

  2013cites this paper
• UDP-Glucuronosyltransferase 1A Compromises Intracellular Accumulation and Anti-Cancer Effect of Tanshinone IIA in Human Colon Cancer Cells

  2013cites this paper
• CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

  2013cites this paper
• Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer

  2013cites this paper
• PharmGKB summary: tamoxifen pathway, pharmacokinetics

  2013cites this paper
• Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival

  2013cites this paper
• Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies

  2013cites this paper
• Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective

  2012cites this paper
• Identification and Functional Characterization of a Novel UDP-Glucuronosyltransferase 2A1 Splice Variant: Potential Importance in Tobacco-Related Cancer Susceptibility

  2012cites this paper
• CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

  2012cites this paper
• LC-MS in Drug Bioanalysis

  2012cites this paper
• Role of the Uridine Diphosphate Glucuronosyltransferase 2a Family in Tobacco Carcinogen Metabolism

  2012influential citation
• "Citocromo P450 2D6: Variabilidade na terapêutica e na predisposição para patologias"

  2012cites this paper
• 6. Clinical Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors in Prevention and Adjuvant Treatment of Breast Cancer

  2012cites this paper
• Glucuronidation of trans-3′-hydroxycotinine by UGT2B17 and UGT2B10

  2012cites this paper
• Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance

  2012cites this paper
• Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer

  2012cites this paper
• Contributions of human enzymes in carcinogen metabolism.

  2012cites this paper
• SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

  2012cites this paper
• Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.

  2012cites this paper
• Functional Polymorphisms in UDP-Glucuronosyl Transferases and Recurrence in Tamoxifen-Treated Breast Cancer Survivors

  2011cites this paper
• Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

  2011cites this paper
• UDP-glucuronosyltransferase 2B7 glucuronidation of the active tamoxifen metabolites

  2011influential citation
• Automation and Miniaturization of the Bioluminescent UGT-Glo Assay for Screening of UDP-Glucuronosyltransferase Inhibition by Various Compounds

  2011cites this paper
• Pharmacogenetics of endocrine therapy for breast cancer.

  2011cites this paper
• Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis

  2011cites this paper
• First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

  2011cites this paper
• Characterization of dibenzo[a,l]pyrene-trans-11,12-diol (dibenzo[def,p]chrysene) glucuronidation by UDP-glucuronosyltransferases.

  2011cites this paper
• Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

  2010cites this paper
• Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.

  2010cites this paper
• Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics

  2010cites this paper
• A convenient synthesis of (Z)-4-hydroxy-N-desmethyltamoxifen (endoxifen).

  2010cites this paper
• Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue

  2010cites this paper
• CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance

  2010influential citation
• The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

  2010cites this paper
• Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review.

  2010cites this paper
• Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects

  2010cites this paper
• Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives.

  2010cites this paper
• UDP‐Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo

  2010cites this paper
• Herbal interactions with anticancer drugs: mechanistic and clinical considerations.

  2010cites this paper
• Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

  2010influential citation
• Toxicology, Safety and Herb–drug Interactions in Cancer Therapy

  2010cites this paper
• Estimating the impact of molecular profiles and prescription drugs on breast cancer outcomes

  2010cites this paper
• Enzymatic Basis of Phase I and Phase II Drug Metabolism

  2010cites this paper
• Enzyme- and transporter-based drug-drug Interactions : progress and future challenges

  2010cites this paper
• MECHANISMS OF VARIABILITY IN CYP2D6 METABOLISM: THE CONTRIBUTIONS OF POLYMORPHISMS, COPY NUMBER VARIATIONS AND microRNA

  2010cites this paper
• Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder.

  2010cites this paper
• The role of pharmacogenetics in selection of breast cancer treatment

  2009cites this paper
• Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

  2009influential citation
• In vitro glucuronidation of fenofibric acid by human UGTs and liver microsomes.

  2009influential citation
• Functional Characterization of Low-Prevalence Missense Polymorphisms in the UDP-Glucuronosyltransferase 1A9 Gene The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.

  2009cites this paper
• Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention

  2009cites this paper
• Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

  2009cites this paper
• Functional Characterization of Low-Prevalence Missense Polymorphisms in the UGT1A9 Gene

  2009cites this paper
• Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents.

  2009cites this paper
• Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.

  2009influential citation
• In Vitro Glucuronidation of Fenofibric Acid by Human UDP-Glucuronosyltransferases and Liver Microsomes

  2009cites this paper
• Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer

  2009cites this paper